{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:57:43Z","timestamp":1781243863803,"version":"3.54.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403100"],"award-info":[{"award-number":["82403100"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473184"],"award-info":[{"award-number":["82473184"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","award":["24ZR1409900"],"award-info":[{"award-number":["24ZR1409900"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fellowship from the China Postdoctoral Science Foundation","award":["2024M760555"],"award-info":[{"award-number":["2024M760555"]}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"crossref","award":["Y-2024AZ(EGFR)MS-0048"],"award-info":[{"award-number":["Y-2024AZ(EGFR)MS-0048"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-026-03673-8","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:28:48Z","timestamp":1776407328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MXD4 enhances resistance to KRAS G12C-targeted therapy in lung adenocarcinoma by suppressing ACSL4-mediated ferroptosis"],"prefix":"10.1186","volume":"27","author":[{"given":"Yanjun","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shencheng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoshu","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyi","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"issue":"3","key":"3673_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-CANCER J CLIN [J]. 2024;74(3):229\u201363.","journal-title":"CA-CANCER J CLIN [J]"},{"issue":"1","key":"3673_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","volume":"10","author":"L Hendriks","year":"2024","unstructured":"Hendriks L, Remon J, Faivre-Finn C, Garassino MC, Heymach JV, Kerr KM, et al. Non-small-cell lung cancer. NAT REV DIS PRIMERS [J]. 2024;10(1):71.","journal-title":"NAT REV DIS PRIMERS [J]"},{"key":"3673_CR3","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2147\/CMAR.S187317","volume":"11","author":"T Lu","year":"2019","unstructured":"Lu T, Yang X, Huang Y, Zhao M, Li M, Ma K, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. CANCER MANAG RES [J]. 2019;11:943\u201353.","journal-title":"CANCER MANAG RES [J]"},{"issue":"1","key":"3673_CR4","doi-asserted-by":"publisher","first-page":"398","DOI":"10.21037\/jtd.2017.12.68","volume":"10","author":"M Zhao","year":"2018","unstructured":"Zhao M, Zhan C, Li M, Yang X, Yang X, Zhang Y, et al. Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma. J THORAC DIS [J]. 2018;10(1):398\u2013407.","journal-title":"J THORAC DIS [J]"},{"issue":"2","key":"3673_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","volume":"11","author":"T Isermann","year":"2025","unstructured":"Isermann T, Sers C, Der CJ, Papke B. KRAS inhibitors: resistance drivers and combinatorial strategies. TRENDS CANCER [J]. 2025;11(2):91\u2013116.","journal-title":"TRENDS CANCER [J]"},{"issue":"5","key":"3673_CR6","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41568-024-00679-6","volume":"24","author":"N Perurena","year":"2024","unstructured":"Perurena N, Situ L, Cichowski K. Combinatorial strategies to target RAS-driven cancers. NAT REV CANCER [J]. 2024;24(5):316\u201337.","journal-title":"NAT REV CANCER [J]"},{"issue":"4","key":"3673_CR7","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","volume":"30","author":"A Singhal","year":"2024","unstructured":"Singhal A, Li BT, O\u2019Reilly EM. Targeting KRAS in cancer. NAT MED [J]. 2024;30(4):969\u201383.","journal-title":"NAT MED [J]"},{"issue":"1","key":"3673_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, et al. The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. CANCER DISCOV [J]. 2020;10(1):54\u201371.","journal-title":"CANCER DISCOV [J]"},{"issue":"13","key":"3673_CR9","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors. NEW ENGL J MED [J]. 2020;383(13):1207\u201317.","journal-title":"NEW ENGL J MED [J]"},{"issue":"12","key":"3673_CR10","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.jtho.2024.08.005","volume":"19","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Meng X, Sun L, Huang D, Yang N, Yu Y, et al. Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study. J THORAC ONCOL [J]. 2024;19(12):1630\u20139.","journal-title":"J THORAC ONCOL [J]"},{"issue":"8","key":"3673_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S2213-2600(24)00110-3","volume":"12","author":"Z Li","year":"2024","unstructured":"Li Z, Dang X, Huang D, Jin S, Li W, Shi J, et al. Garsorasib in patients with KRAS(G12C)-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial. LANCET RESP MED [J]. 2024;12(8):589\u201398.","journal-title":"LANCET RESP MED [J]"},{"issue":"3","key":"3673_CR12","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/s41591-024-03401-z","volume":"31","author":"Y Shi","year":"2025","unstructured":"Shi Y, Fang J, Xing L, Yao Y, Zhang J, Liu L, et al. Glecirasib in KRAS(G12C)-mutated nonsmall-cell lung cancer: a phase 2b trial. NAT MED [J]. 2025;31(3):894\u2013900.","journal-title":"NAT MED [J]"},{"issue":"6758","key":"3673_CR13","doi-asserted-by":"publisher","first-page":"eads0239","DOI":"10.1126\/science.ads0239","volume":"389","author":"C Weller","year":"2025","unstructured":"Weller C, Burnett GL, Jiang L, Chakraborty S, Zhang D, Vita NA, et al. A neomorphic protein interface catalyzes covalent inhibition of RAS(G12D) aspartic acid in tumors. Sci [J]. 2025;389(6758):eads0239.","journal-title":"Sci [J]"},{"issue":"8013","key":"3673_CR14","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s41586-024-07205-6","volume":"629","author":"M Holderfield","year":"2024","unstructured":"Holderfield M, Lee BJ, Jiang J, Tomlinson A, Seamon KJ, Mira A, et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nat [J]. 2024;629(8013):919\u201326.","journal-title":"Nat [J]"},{"issue":"6","key":"3673_CR15","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.annonc.2025.01.020","volume":"36","author":"JM Riedl","year":"2025","unstructured":"Riedl JM, De La Cruz F, Lin F, Parseghian JJ, Kim C, Matsubara JE. Genomic landscape of clinically acquired resistance alterations in patients treated with KRAS(G12C) inhibitors. ANN ONCOL [J]. 2025;36(6):682\u201392.","journal-title":"ANN ONCOL [J]"},{"issue":"1","key":"3673_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-024-01631-9","volume":"17","author":"X Yang","year":"2024","unstructured":"Yang X, Wu H. RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms. J HEMATOL ONCOL [J]. 2024;17(1):108.","journal-title":"J HEMATOL ONCOL [J]"},{"issue":"43","key":"3673_CR17","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1038\/s41388-025-03563-1","volume":"44","author":"G Bove","year":"2025","unstructured":"Bove G, Babaei M, Bueno-Costa A, Amin S, Simonelli N, Benedetti R, et al. METTL16-mediated inhibition of MXD4 promotes leukemia through activation of the MYC-MAX axis. ONCOGENE [J]. 2025;44(43):4159\u201372.","journal-title":"ONCOGENE [J]"},{"issue":"2","key":"3673_CR18","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.cell.2024.10.047","volume":"188","author":"Y Wang","year":"2025","unstructured":"Wang Y, Hu M, Cao J, Wang F, Han JR, Wu TW, et al. ACSL4 and polyunsaturated lipids support metastatic extravasation and colonization. CELL [J]. 2025;188(2):412\u201329.","journal-title":"CELL [J]"},{"issue":"7","key":"3673_CR19","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.tem.2024.09.003","volume":"36","author":"J Lin","year":"2025","unstructured":"Lin J, Lai Y, Lu F, Wang W. Targeting ACSLs to modulate ferroptosis and cancer immunity. TRENDS ENDOCRIN MET [J]. 2025;36(7):677\u201390.","journal-title":"TRENDS ENDOCRIN MET [J]"},{"issue":"1","key":"3673_CR20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41421-025-00829-6","volume":"11","author":"G Shan","year":"2025","unstructured":"Shan G, Bian Y, Sui Q, Liang J, Ren S, Pan B, et al. Ferroptosis-induced SUMO2 lactylation counteracts ferroptosis by enhancing ACSL4 degradation in lung adenocarcinoma. CELL DISCOV [J]. 2025;11(1):81.","journal-title":"CELL DISCOV [J]"},{"key":"3673_CR21","first-page":"24","volume":"106","author":"CC Uphoff","year":"2014","unstructured":"Uphoff CC, Drexler HG. Detection of Mycoplasma contamination in cell cultures. Curr Protoc Mol Biol [J]. 2014;106:24\u20138.","journal-title":"Curr Protoc Mol Biol [J]"},{"issue":"2","key":"3673_CR22","doi-asserted-by":"publisher","first-page":"113771","DOI":"10.1016\/j.celrep.2024.113771","volume":"43","author":"J Liang","year":"2024","unstructured":"Liang J, Bi G, Sui Q, Zhao G, Zhang H, Bian Y, et al. Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma. CELL REP [J]. 2024;43(2):113771.","journal-title":"CELL REP [J]"},{"key":"3673_CR23","doi-asserted-by":"publisher","first-page":"101057","DOI":"10.1016\/j.drup.2024.101057","volume":"73","author":"J Liang","year":"2024","unstructured":"Liang J, Bi G, Huang Y, Zhao G, Sui Q, Zhang H, et al. MAFF confers vulnerability to cisplatin-based and ionizing radiation treatments by modulating ferroptosis and cell cycle progression in lung adenocarcinoma. DRUG RESIST UPDATE [J]. 2024;73:101057.","journal-title":"DRUG RESIST UPDATE [J]"},{"key":"3673_CR24","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1038\/s41467-024-46776-w","volume":"15","author":"G Bi","year":"2024","unstructured":"Bi G, Liang J, Bian Y, Shan G, Huang Y, Lu T, et al. Polyamine-mediated ferroptosis amplification acts as a targetable vulnerability in cancer. NAT COMMUN [J]. 2024;15:2461.","journal-title":"NAT COMMUN [J]"},{"key":"3673_CR25","doi-asserted-by":"publisher","first-page":"9923","DOI":"10.1038\/s41467-025-65441-4","volume":"16","author":"Y Bian","year":"2025","unstructured":"Bian Y, Shan G, Bi G, Xu Z, Liang J, Yan Y, et al. Targeting polyamine metabolism and ferroptosis enhances the efficacy of KRAS-targeted therapy depending on KEAP1 status. NAT COMMUN [J]. 2025;16:9923.","journal-title":"NAT COMMUN [J]"},{"issue":"1","key":"3673_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40164-025-00657-0","volume":"14","author":"G Shan","year":"2025","unstructured":"Shan G, Bian Y, Ren S, Hu Z, Pan B, Zeng D, et al. Sarcosine sensitizes lung adenocarcinoma to chemotherapy by dual activation of ferroptosis via PDK4\/PDHA1 signaling and NMDAR-mediated iron export. EXP HEMATOL ONCOL [J]. 2025;14(1):60.","journal-title":"EXP HEMATOL ONCOL [J]"},{"key":"3673_CR27","doi-asserted-by":"publisher","first-page":"103361","DOI":"10.1016\/j.redox.2024.103361","volume":"77","author":"Y Bian","year":"2024","unstructured":"Bian Y, Shan G, Bi G, Liang J, Hu Z, Sui Q, et al. Targeting ALDH1A1 to enhance the efficacy of KRAS-targeted therapy through ferroptosis. REDOX BIOL [J]. 2024;77:103361.","journal-title":"REDOX BIOL [J]"},{"issue":"14","key":"3673_CR28","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1158\/0008-5472.CAN-22-3977","volume":"83","author":"G Bi","year":"2023","unstructured":"Bi G, Liang J, Shan G, Bian Y, Chen Z, Huang Y, et al. Retinol Saturase Mediates Retinoid Metabolism to Impair a Ferroptosis Defense System in Cancer Cells. CANCER RES [J]. 2023;83(14):2387\u2013404.","journal-title":"CANCER RES [J]"},{"issue":"11","key":"3673_CR29","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/cac2.70068","volume":"45","author":"J Liang","year":"2025","unstructured":"Liang J, Bi G, Huang X, Xu Z, Huang Y, Bian Y, et al. CD24 is a promising immunotherapeutic target for enhancing efficacy of third-generation EGFR-TKIs on EGFR-mutated lung cancer. CANCER COMMUN [J]. 2025;45(11):1547\u201378.","journal-title":"CANCER COMMUN [J]"},{"issue":"1","key":"3673_CR30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12931-025-03278-7","volume":"26","author":"S Ren","year":"2025","unstructured":"Ren S, Zhu J, Shan G, Liang J, Bian Y, Lin H, et al. Transcription factor ZNF266 suppresses cancer progression by modulating CA9-mediated intracellular pH alteration in lung adenocarcinoma. RESP RES [J]. 2025;26(1):191.","journal-title":"RESP RES [J]"},{"key":"3673_CR31","doi-asserted-by":"crossref","unstructured":"Huang X, Liang J, Yi Y, Zhu J, Lin H, Ren S et al. Targeting inosine metabolism to enhance EGFR-targeted therapy in lung adenocarcinoma. CANCER LETT. [J]. 2025;634(2025):218069.","DOI":"10.1016\/j.canlet.2025.218069"},{"key":"3673_CR32","doi-asserted-by":"publisher","first-page":"8181","DOI":"10.1038\/s41467-025-63687-6","volume":"16","author":"G Bi","year":"2025","unstructured":"Bi G, Liang J, Bian Y, Shan G, Ren S, Shi H, et al. Targeting ALDH16A1 mediated thioredoxin lysosomal degradation to enhance ferroptosis susceptibility in SMARCA4-deficient NSCLC. NAT COMMUN [J]. 2025;16:8181.","journal-title":"NAT COMMUN [J]"},{"key":"3673_CR33","doi-asserted-by":"publisher","first-page":"216497","DOI":"10.1016\/j.canlet.2023.216497","volume":"581","author":"Q Sui","year":"2024","unstructured":"Sui Q, Hu Z, Liang J, Lu T, Bian Y, Jin X, et al. Targeting TAM-secreted S100A9 effectively enhances the tumor-suppressive effect of metformin in treating lung adenocarcinoma. CANCER LETT [J]. 2024;581:216497.","journal-title":"CANCER LETT [J]"},{"issue":"D1","key":"3673_CR34","doi-asserted-by":"publisher","first-page":"D174","DOI":"10.1093\/nar\/gkad1059","volume":"52","author":"I Rauluseviciute","year":"2024","unstructured":"Rauluseviciute I, Riudavets-Puig R, Blanc-Mathieu R, Castro-Mondragon JA, Ferenc K, Kumar V, et al. JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profiles. NUCLEIC ACIDS RES [J]. 2024;52(D1):D174\u201382.","journal-title":"NUCLEIC ACIDS RES [J]"},{"issue":"8","key":"3673_CR35","doi-asserted-by":"publisher","first-page":"101663","DOI":"10.1016\/j.xcrm.2024.101663","volume":"5","author":"M Nokin","year":"2024","unstructured":"Nokin M, Darbo E, Richard E, San Jos\u00e9 S, de Hita S, Prouzet-Mauleon V, et al. In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF(V600E) lung adenocarcinoma. CELL REP MED [J]. 2024;5(8):101663.","journal-title":"CELL REP MED [J]"},{"issue":"6","key":"3673_CR36","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s43018-023-00577-0","volume":"4","author":"TJ Hagenbeek","year":"2023","unstructured":"Hagenbeek TJ, Zbieg JR, Hafner M, Mroue R, Lacap JA, Sodir NM, et al. An allosteric pan-TEAD inhibitor blocks oncogenic YAP\/TAZ signaling and overcomes KRAS G12C inhibitor resistance. NAT CANCER [J]. 2023;4(6):812\u201328.","journal-title":"NAT CANCER [J]"},{"issue":"18","key":"3673_CR37","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1158\/0008-5472.CAN-25-1464","volume":"85","author":"N Knoll","year":"2025","unstructured":"Knoll N, Masser S, Bordas B, Ebright RY, Li G, Kesar D, et al. CRISPR-Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer. CANCER RES [J]. 2025;85(18):3518\u201339.","journal-title":"CANCER RES [J]"},{"issue":"2","key":"3673_CR38","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1158\/0008-5472.CAN-25-0450","volume":"86","author":"YE Stern","year":"2026","unstructured":"Stern YE, Ghosh P, Peroza J, Solanki HS, Imbody D, Bridenstine L, et al. Targeting CDK12\/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors. CANCER RES [J]. 2026;86(2):485\u2013502.","journal-title":"CANCER RES [J]"},{"key":"3673_CR39","doi-asserted-by":"crossref","unstructured":"Salm\u00f3n M, \u00c1lvarez-D\u00edaz R, Fustero-Torre C, Brehey O, Lechuga CG, Sanclemente M et al. Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas. J CLIN INVEST. [J]. 2023;133(7):e164413.","DOI":"10.1172\/JCI164413"},{"issue":"2","key":"3673_CR40","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1158\/0008-5472.CAN-25-0600","volume":"86","author":"HS Solanki","year":"2026","unstructured":"Solanki HS, Shah H, Imbody D, Desai B, Kato R, Miroshnychenko D, et al. RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non-Small Cell Lung Cancer. CANCER RES [J]. 2026;86(2):467\u201384.","journal-title":"CANCER RES [J]"},{"issue":"8","key":"3673_CR41","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1038\/s41591-025-03732-5","volume":"31","author":"F Skoulidis","year":"2025","unstructured":"Skoulidis F, Li BT, de Langen AJ, Hong DS, Lena H, Wolf J, et al. Molecular determinants of sotorasib clinical efficacy in KRAS(G12C)-mutated non-small-cell lung cancer. NAT MED [J]. 2025;31(8):2755\u201367.","journal-title":"NAT MED [J]"},{"issue":"D1","key":"3673_CR42","doi-asserted-by":"publisher","first-page":"D882","DOI":"10.1093\/nar\/gkz1062","volume":"48","author":"Y Luo","year":"2020","unstructured":"Luo Y, Hitz BC, Gabdank I, Hilton JA, Kagda MS, Lam B, et al. New developments on the Encyclopedia of DNA Elements (ENCODE) data portal. NUCLEIC ACIDS RES [J]. 2020;48(D1):D882\u20139.","journal-title":"NUCLEIC ACIDS RES [J]"},{"issue":"D1","key":"3673_CR43","doi-asserted-by":"publisher","first-page":"D104","DOI":"10.1093\/nar\/gkaa1057","volume":"49","author":"S Kolmykov","year":"2021","unstructured":"Kolmykov S, Yevshin I, Kulyashov M, Sharipov R, Kondrakhin Y, Makeev VJ, et al. GTRD: an integrated view of transcription regulation. NUCLEIC ACIDS RES [J]. 2021;49(D1):D104\u201311.","journal-title":"NUCLEIC ACIDS RES [J]"},{"issue":"2","key":"3673_CR44","doi-asserted-by":"publisher","first-page":"106080","DOI":"10.1016\/j.isci.2023.106080","volume":"26","author":"Y Wang","year":"2023","unstructured":"Wang Y, Zhong B, Xu C, Zhan D, Zhao S, Wu H, et al. Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target. ISCIENCE [J]. 2023;26(2):106080.","journal-title":"ISCIENCE [J]"},{"issue":"10","key":"3673_CR45","first-page":"1499","volume":"42","author":"I Marchal","year":"2024","unstructured":"Marchal I. Pan-KRAS destruction with a single PROTAC. NAT BIOTECHNOL [J]. 2024;42(10):1499.","journal-title":"NAT BIOTECHNOL [J]"},{"key":"3673_CR46","doi-asserted-by":"crossref","unstructured":"Bear AS, Nadler RB, O\u2019Hara MH, Stanton KL, Xu C, Saporito RJ et al. Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors. J CLIN INVEST [J]. 2024;134(21):e175790.","DOI":"10.1172\/JCI175790"},{"issue":"1","key":"3673_CR47","doi-asserted-by":"publisher","first-page":"6389","DOI":"10.1038\/s41467-023-42010-1","volume":"14","author":"D Lu","year":"2023","unstructured":"Lu D, Chen Y, Jiang M, Wang J, Li Y, Ma K, et al. KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors. NAT COMMUN [J]. 2023;14(1):6389.","journal-title":"NAT COMMUN [J]"},{"issue":"8","key":"3673_CR48","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","volume":"10","author":"V Amodio","year":"2020","unstructured":"Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, et al. EGFR Blockade Reverts Resistance to KRAS(G12C) Inhibition in Colorectal Cancer. CANCER DISCOV [J]. 2020;10(8):1129\u201339.","journal-title":"CANCER DISCOV [J]"},{"issue":"11","key":"3673_CR49","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","volume":"14","author":"J Dilly","year":"2024","unstructured":"Dilly J, Hoffman MT, Abbassi L, Li Z, Paradiso F, Parent BD, et al. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. CANCER DISCOV [J]. 2024;14(11):2135\u201361.","journal-title":"CANCER DISCOV [J]"},{"issue":"7886","key":"3673_CR50","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","volume":"599","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Murciano-Goroff YR, Xue JY, Ang A, Lucas J, Mai TT, et al. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nat [J]. 2021;599(7886):679\u201383.","journal-title":"Nat [J]"},{"issue":"12","key":"3673_CR51","doi-asserted-by":"publisher","first-page":"110993","DOI":"10.1016\/j.celrep.2022.110993","volume":"39","author":"MB Ryan","year":"2022","unstructured":"Ryan MB, Coker O, Sorokin A, Fella K, Barnes H, Wong E, et al. KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy. CELL REP [J]. 2022;39(12):110993.","journal-title":"CELL REP [J]"},{"issue":"1","key":"3673_CR52","doi-asserted-by":"publisher","first-page":"7554","DOI":"10.1038\/s41467-024-51828-2","volume":"15","author":"M Nokin","year":"2024","unstructured":"Nokin M, Mira A, Patrucco E, Ricciuti B, Cousin S, Soubeyran I, et al. RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade. NAT COMMUN [J]. 2024;15(1):7554.","journal-title":"NAT COMMUN [J]"},{"issue":"11","key":"3673_CR53","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1158\/2159-8290.CD-24-0421","volume":"14","author":"HA Araujo","year":"2024","unstructured":"Araujo HA, Pechuan-Jorge X, Zhou T, Do MT, Hu X, Rojas Alvarez FR, et al. Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung Cancer. CANCER DISCOV [J]. 2024;14(11):2183\u2013208.","journal-title":"CANCER DISCOV [J]"},{"issue":"6","key":"3673_CR54","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","volume":"14","author":"J Jiang","year":"2024","unstructured":"Jiang J, Jiang L, Maldonato BJ, Wang Y, Holderfield M, Aronchik I, et al. Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers. CANCER DISCOV [J]. 2024;14(6):994\u20131017.","journal-title":"CANCER DISCOV [J]"},{"issue":"12","key":"3673_CR55","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41422-022-00735-6","volume":"32","author":"C Hu","year":"2022","unstructured":"Hu C, Chen B, Li Z, Yang T, Xu C, Yang R, et al. Targeting UHRF1-SAP30-MXD4 axis for leukemia initiating cell eradication in myeloid leukemia. CELL RES [J]. 2022;32(12):1105\u201323.","journal-title":"CELL RES [J]"},{"issue":"13","key":"3673_CR56","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.4161\/cbt.21814","volume":"13","author":"W Yang","year":"2012","unstructured":"Yang W, Yang X, David G, Dorsey JF. Dissecting the complex regulation of Mad4 in glioblastoma multiforme cells. CANCER BIOL THER [J]. 2012;13(13):1339\u201348.","journal-title":"CANCER BIOL THER [J]"},{"issue":"10","key":"3673_CR57","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1158\/2159-8290.CD-20-1540","volume":"11","author":"M Heckler","year":"2021","unstructured":"Heckler M, Ali LR, Clancy-Thompson E, Qiang L, Ventre KS, Lenehan P, et al. Inhibition of CDK4\/6 Promotes CD8 T-cell Memory Formation. CANCER DISCOV [J]. 2021;11(10):2564\u201381.","journal-title":"CANCER DISCOV [J]"},{"issue":"10","key":"3673_CR58","doi-asserted-by":"publisher","first-page":"100816","DOI":"10.1016\/j.modpat.2025.100816","volume":"38","author":"Z Alsugair","year":"2025","unstructured":"Alsugair Z, Karanian M, Meurgey A, Treilleux I, Renard C, Phelinas S, et al. NUTM1\/NUTM2B-Rearranged Intra-abdominal Sarcomas: A Distinct Entity From Sarcomas With ESR1 Overexpression as a Therapeutic Target. Mod PATHOL [J]. 2025;38(10):100816.","journal-title":"Mod PATHOL [J]"},{"issue":"5","key":"3673_CR59","doi-asserted-by":"publisher","first-page":"100729","DOI":"10.1016\/j.modpat.2025.100729","volume":"38","author":"DJJ Papke","year":"2025","unstructured":"Papke DJJ, Chrisinger JSA, French CA, Crymes A, Krivak TC, Estape RE, et al. MAD::NUT Fusion Sarcoma: A Sarcoma Class With NUTM1, NUTM2A, and NUTM2G Fusions and Possibly Distinctive Subtypes. Mod PATHOL [J]. 2025;38(5):100729.","journal-title":"Mod PATHOL [J]"},{"issue":"8","key":"3673_CR60","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1038\/s41379-021-00792-z","volume":"34","author":"BJ Van Treeck","year":"2021","unstructured":"Van Treeck BJ, Thangaiah JJ, Torres-Mora J, Stevens TM, Rothermundt C, Fassan M, et al. NUTM1-rearranged colorectal sarcoma: a clinicopathologically and genetically distinctive malignant neoplasm with a poor prognosis. Mod PATHOL [J]. 2021;34(8):1547\u201357.","journal-title":"Mod PATHOL [J]"},{"key":"3673_CR61","doi-asserted-by":"crossref","unstructured":"Crunkhorn S. Triggering ferroptosis in drug-tolerant cancer cells. NAT REV DRUG DISCOV. [J]; 2025;24(7):501.","DOI":"10.1038\/d41573-025-00090-2"},{"key":"3673_CR62","doi-asserted-by":"crossref","unstructured":"Ubellacker JM, Dixon SJ. Prospects for ferroptosis therapies in cancer. NAT CANCER. [J]. 2025;6(8):1326\u201336.","DOI":"10.1038\/s43018-025-01037-7"},{"key":"3673_CR63","doi-asserted-by":"publisher","first-page":"103211","DOI":"10.1016\/j.redox.2024.103211","volume":"75","author":"C Berndt","year":"2024","unstructured":"Berndt C, Alborzinia H, Amen VS, Ayton S, Barayeu U, Bartelt A, et al. Ferroptosis in health and disease. REDOX BIOL [J]. 2024;75:103211.","journal-title":"REDOX BIOL [J]"},{"key":"3673_CR64","doi-asserted-by":"crossref","unstructured":"Dixon SJ, Olzmann JA. The cell biology of ferroptosis. NAT REV MOL CELL BIO. [J]; 2024;25(6):424\u201342.","DOI":"10.1038\/s41580-024-00703-5"},{"issue":"12","key":"3673_CR65","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.tcb.2023.05.003","volume":"33","author":"LE Pope","year":"2023","unstructured":"Pope LE, Dixon SJ. Regulation of ferroptosis by lipid metabolism. TRENDS CELL BIOL [J]. 2023;33(12):1077\u201387.","journal-title":"TRENDS CELL BIOL [J]"},{"issue":"1","key":"3673_CR66","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-022-01004-z","volume":"7","author":"B Gan","year":"2022","unstructured":"Gan B. ACSL4, PUFA, and ferroptosis: new arsenal in anti-tumor immunity. SIGNAL TRANSDUCT TAR [J]. 2022;7(1):128.","journal-title":"SIGNAL TRANSDUCT TAR [J]"},{"issue":"3","key":"3673_CR67","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s43018-021-00184-x","volume":"2","author":"S Mukhopadhyay","year":"2021","unstructured":"Mukhopadhyay S, Vander Heiden MG, McCormick F. The Metabolic Landscape of RAS-Driven Cancers from biology to therapy. NAT CANCER [J]. 2021;2(3):271\u201383.","journal-title":"NAT CANCER [J]"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03673-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03673-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03673-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:10:01Z","timestamp":1781241001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03673-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3673"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03673-8","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"11 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was duly obtained from all participants regarding the use of their tumor samples and clinicopathological data, strictly following the Declaration of Helsinki. The study protocol was reviewed and approved by the Ethics Committee of Zhongshan Hospital, Fudan University (Approval No.: B2022-180R).Animal experiments were conducted in accordance with the World Medical Association (WMA) Statement on the Use of Animals in Biomedical Research and the ethical guidelines established by the Animal Ethics Committee of Zhongshan Hospital, Fudan University (Approval No.: 2024-262). Tumor diameters were closely monitored throughout the experimental period to ensure that the tumor diameters of all mice did not exceed 2 cm.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent to participate and to publish was obtained from participants before inclusion in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"237"}}